

It is therefore an object of the invention to provide an improved method of production of large lots of Poly-ICLC, suitable for clinical use.

It is a further object of the invention to provide an improved method for administration of Poly-ICLC that results in markedly decreased toxicity, and marked enhancement of its clinical and veterinary uses and its multidimensional biological effects.

It is a further object of the invention to provide a method of using Poly-ICLC to provide gene-regulatory actions in humans.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a table showing Systemic Response to a Single Intranasal dose of Poly-ICLC in Rhesus Monkeys

Figure 2 is a table showing induction of Interferon in Rhesus Monkeys by 2mg/kg IV of Poly-ICLC manufactured as described in the present application (lot # RBP 10036) (Compare to table I in Levy'82, patent #4,349,538, In spite of a higher dose of 3 mg/kg, the Levy preparation induced lower levels of interferon in Rhesus monkeys.)

Figure 3 is a table showing Particulate testing (clarity) of Poly-ICLC components and final product as described in the present application

Table 4

Figure 4 is a table of unpublished survival data in malignant glioma patients treated with long term, low dose Poly-ICLC.

Figure 5 is a table showing decrease or stabilization of HIV viral load after treatment of advanced AIDS patients with low dose, long term Poly-ICLC.

AMW
7-8-08